<div id="readability-page-1">Envestnet Asset Management Inc. raised its holdings in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 5.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,138,576 shares of the company's stock after buying an additional 119,759 shares during the period. Envestnet Asset Management Inc. owned about 0.31% of Corteva worth $144,640,000 at the end of the most recent reporting period.<ul><li>These 3 Stocks Just Got Upgraded—and Could Keep Climbing</li></ul>Other hedge funds have also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC grew its position in Corteva by 40.3% in the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 8,618 shares of the company's stock valued at $583,000 after acquiring an additional 2,476 shares during the last quarter. Premier Path Wealth Partners LLC boosted its stake in shares of Corteva by 4.3% during the third quarter. Premier Path Wealth Partners LLC now owns 10,947 shares of the company's stock valued at $740,000 after purchasing an additional 456 shares during the period. Compass Financial Services Inc bought a new position in shares of Corteva in the third quarter worth about $34,000. Physician Wealth Advisors Inc. grew its holdings in shares of Corteva by 85.1% in the third quarter. Physician Wealth Advisors Inc. now owns 498 shares of the company's stock worth $34,000 after purchasing an additional 229 shares during the last quarter. Finally, Simmons Bank increased its stake in Corteva by 3.8% in the 3rd quarter. Simmons Bank now owns 40,515 shares of the company's stock worth $2,740,000 after buying an additional 1,471 shares during the period. Institutional investors own 81.54% of the company's stock. <h2>Wall Street Analysts Forecast Growth</h2>CTVA has been the topic of a number of research analyst reports. Wells Fargo &amp; Company upped their target price on shares of Corteva from $77.00 to $85.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday. The Goldman Sachs Group reiterated a &#34;buy&#34; rating and issued a $88.00 price target on shares of Corteva in a report on Thursday. Wall Street Zen cut Corteva from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Citigroup lifted their target price on Corteva from $74.00 to $80.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday. Finally, Zacks Research raised Corteva from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Corteva presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $82.37.<ul><li>How Trump’s AI Push Could Boost These 3 Agriculture Stocks</li></ul>View Our Latest Research Report on Corteva<h2>Corteva Trading Up 0.2%</h2>NYSE:CTVA opened at $72.63 on Friday. The stock has a market capitalization of $49.08 billion, a price-to-earnings ratio of 45.97, a PEG ratio of 1.84 and a beta of 0.75. Corteva, Inc. has a 52 week low of $53.40 and a 52 week high of $77.41. The company has a quick ratio of 1.07, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The firm has a 50 day moving average of $68.82 and a 200 day moving average of $68.42. <ul><li>2 Agriculture Stocks To Benefit From a Trump Presidency in 2025 </li></ul>Corteva (NYSE:CTVA - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The business's revenue for the quarter was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts anticipate that Corteva, Inc. will post 2.96 earnings per share for the current fiscal year. <h2>Corteva Announces Dividend</h2>The firm also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Monday, March 2nd will be paid a $0.18 dividend. The ex-dividend date is Monday, March 2nd. This represents a $0.72 dividend on an annualized basis and a yield of 1.0%. Corteva's dividend payout ratio (DPR) is 45.57%. <h2>Corteva News Roundup</h2>Here are the key news stories impacting Corteva this week:<ul> <li>Positive Sentiment: Several sell‑side firms lifted targets and kept bullish ratings, signaling analyst confidence in longer‑term upside: Deutsche Bank to $90 (buy), Wolfe Research to $86 (outperform), and RBC to $89 (outperform). Deutsche Bank raise Wolfe Research raise RBC raise</li> <li>Positive Sentiment: Brokerage consensus remains constructive (consensus &#34;Moderate Buy&#34;), which supports demand for the shares despite near‑term noise. Consensus Moderate Buy</li> <li>Positive Sentiment: Strategic commentary highlights Corteva’s expanding role in global agriculture and technology leadership—positive for medium‑term growth expectations. Corteva expands role</li> <li>Neutral Sentiment: Analyst views are mixed across publications — some highlight long‑term upside tied to licensing and settlements, while others argue valuation limits near‑term gains. Investors should weigh catalyst timing. Bull case analysis Conflicting analyst views</li> <li>Neutral Sentiment: Technical analysis pieces warn of a key structural test — useful for traders but not definitive for fundamentals; could increase short‑term volatility. Technical caution</li> <li>Negative Sentiment: Q4 results missed revenue expectations (seasonal timing and weaker crop‑protection/seed demand); revenue miss and a wider loss drove an after‑hours selloff. Those operational misses are the main near‑term headwind. Q4 revenue miss After‑hours fall</li> <li>Negative Sentiment: JPMorgan downgraded Corteva from overweight to neutral (citing valuation/limited near‑term upside), which can cool momentum among institutional buyers. JPMorgan downgrade</li> <li>Negative Sentiment: Market reaction to the earnings miss (seasonal timing) and mixed guidance elements increases short‑term uncertainty even as analysts argue for longer‑term upside — expect higher intraday volatility. Seasonal timing impact</li> </ul><h2>About Corteva</h2> (Free Report)Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production. Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.<h2>Featured Articles</h2><ul><li>Five stocks we like better than Corteva</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>Buy this stock tomorrow?</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNUVkE?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNUVkE"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Corteva Right Now?</h2>Before you consider Corteva, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corteva wasn't on the list.While Corteva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

CTVA

FTAG

VEGI

Envestnet Asset Management Inc. increased its stake in Corteva, Inc. by 5.9% in Q3, acquiring 119,759 shares, bringing its total to 2,138,576 shares valued at $144.64 million. Other hedge funds also raised their positions. Analysts have mixed ratings on Corteva, with target prices ranging from $74 to $88. The stock opened at $72.63, with a market cap of $49.08 billion. Corteva reported Q4 earnings of $0.22 per share, matching estimates, and declared a quarterly dividend of $0.18, payable on March 16.

Market Beat

VanEck Agribusiness ETF

Corteva

First Trust Indxx Global Agri

iShares MSCI Agriculture Producers ETF

Invesco DB Agriculture FD ETF

Envestnet Asset Management Inc. Purchases 119,759 Shares of Corteva, Inc. $CTVA